-
EP2440251
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2440251
| EP2440251 - ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 18.08.2017 Database last updated on 16.11.2024 | |
| Former | Grant of patent is intended Status updated on 08.11.2016 | Most recent event Tooltip | 18.08.2017 | Application deemed to be withdrawn | published on 20.09.2017 [2017/38] | Applicant(s) | For all designated states Defyrus, Inc . Suite 2602 2 Bloor Street Toronto, Ontario M4W 3E2 / CA | [2012/16] | Inventor(s) | 01 /
TURNER, Jeffrey D. Suite 2602 2 Bloor Street Toronto Ontario M4W 3E2 / CA | 02 /
ENNIS, Jane E . Suite 2602 2 Bloor Street Toronto Ontario M4W 3E2 / CA | [2012/16] | Representative(s) | HGF HGF Limited Mill House North Street York YO1 6JD / GB | [N/P] |
| Former [2012/16] | Harrison Goddard Foote Saviour House 9 St Saviourgate York YO1 8NQ / GB | Application number, filing date | 10785615.5 | 08.06.2010 | WO2010CA00844 | Priority number, date | US20090185261P | 09.06.2009 Original published format: US 185261 P | [2012/16] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010142017 | Date: | 16.12.2010 | Language: | EN | [2010/50] | Type: | A1 Application with search report | No.: | EP2440251 | Date: | 18.04.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.12.2010 takes the place of the publication of the European patent application. | [2012/16] | Search report(s) | International search report - published on: | CA | 16.12.2010 | (Supplementary) European search report - dispatched on: | EP | 19.12.2012 | Classification | IPC: | A61K38/21, A61K48/00, A61K9/00 | [2016/44] | CPC: |
A61K38/212 (EP,US);
A61K39/12 (US);
A61K48/005 (EP,US);
A61K9/0073 (US);
A61M11/02 (US);
A61M15/00 (US);
A61M16/14 (US);
A61P31/00 (EP);
A61P31/04 (EP);
A61P31/10 (EP);
A61P31/12 (EP);
A61P31/14 (EP);
A61P31/16 (EP);
A61P31/18 (EP);
A61P31/20 (EP);
A61P31/22 (EP);
A61P33/00 (EP);
A61P33/02 (EP);
A61P33/06 (EP);
A61P35/00 (EP);
A61P37/00 (EP);
A61P37/02 (EP);
A61P37/04 (EP);
C12N15/86 (US);
A61K9/0043 (EP,US);
A61K9/007 (EP,US);
C12N2799/022 (EP,US);
Y02A50/30 (EP,US)
(-)
|
| Former IPC [2012/16] | A61K48/00, A61P31/00, A61P37/04, A61K38/21 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/16] | Title | German: | VERABREICHUNG VON INTERFERON ZUR PROPHYLAXE GEGEN ODER ZUR BEHANDLUNG VON KRANKHEITSERREGENDEN INFEKTIONEN | [2012/16] | English: | ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION | [2012/16] | French: | ADMINISTRATION D'INTERFÉRON POUR UNE PROPHYLAXIE CONTRE UNE INFECTION PATHOGÈNE OU UN TRAITEMENT D'UNE INFECTION PATHOGÈNE | [2012/16] | Entry into regional phase | 09.01.2012 | National basic fee paid | 09.01.2012 | Search fee paid | 09.01.2012 | Designation fee(s) paid | 09.01.2012 | Examination fee paid | Examination procedure | 09.01.2012 | Examination requested [2012/16] | 17.07.2013 | Amendment by applicant (claims and/or description) | 06.08.2015 | Despatch of a communication from the examining division (Time limit: M06) | 19.05.2016 | Reply to a communication from the examining division | 17.08.2016 | Despatch of a communication from the examining division (Time limit: M01) | 19.09.2016 | Reply to a communication from the examining division | 09.11.2016 | Communication of intention to grant the patent | 21.03.2017 | Application deemed to be withdrawn, date of legal effect [2017/38] | 26.04.2017 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2017/38] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 06.08.2015 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 19.05.2016 | Request for further processing filed | 19.05.2016 | Full payment received (date of receipt of payment) Request granted | 27.05.2016 | Decision despatched | Fees paid | Renewal fee | 26.06.2012 | Renewal fee patent year 03 | 27.06.2013 | Renewal fee patent year 04 | 30.06.2014 | Renewal fee patent year 05 | 29.06.2015 | Renewal fee patent year 06 | 27.06.2016 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 30.06.2017 | 08 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]US5789245 (DUBENSKY JR THOMAS W [US], et al) [X] 1-7,10 * column 7, line 4 - line 13 * * column 7, line 60 - column 8, line 55 * * column 12, line 43 - column 19, line 58 * * column 21, line 16 - line 20 * * column 37, line 24 - line 32 * * column 43, line 56 - line 64 * * column 44, line 10 - line 44 * * column 151, line 25 - column 152, line 63 * * column 48, line 29 - column 50, line 49 * * column 153, line 47 - column 154, line 2 * * column 154, line 35 - line 50 * * column 130, line 48 - column 140, line 31 *[I] 11-15 | International search | [Y]EP0422697 (AMGEN INC [US]); | [Y]WO9742323 (AMGEN INC [US], et al); | [Y]WO9817801 (CANJI INC [US], et al); | [X]WO0009086 (VALENTIS INC [US], et al); | [Y]WO0009675 (AVENTIS PHARM PROD INC [US], et al); | [Y]EP1078639 (SUMITOMO PHARMA [JP], et al); | Examination | US2006147466 | - M. B. Appaiahgari ET AL, "Seroprevalence of Neutralizing Antibodies to Adenovirus Type 5 among Children in India: Implications for Recombinant Adenovirus-Based Vaccines", CLINICAL AND VACCINE IMMUNOLOGY, US, (20070801), vol. 14, no. 8, doi:10.1128/CVI.00173-07, ISSN 1556-6811, pages 1053 - 1055, XP055309802 DOI: http://dx.doi.org/10.1128/CVI.00173-07 | - Mauro P Moraes ET AL, "pAd5-Blue: Direct Liga - tion System for Engineer - ing Recombinant Adeno - virus Constructs", BioTechniques, (20010901), vol. 31, pages 1050 - 1056, XP055309809 | - BLATT L M ET AL, "THE BIOLOGIC ACTIVITY AND MOLECULAR CHARACTERIZATION OF A NOVEL SYNTHETIC INTERFERON-ALPHA SPECIES, CONSENSUS INTERFERON", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, MARY ANN LIEBERT, NEW YORK, NY, US, (19960101), vol. 16, no. 7, ISSN 1079-9907, pages 489 - 499, XP009023878 | - THE STEP STUDY PROTOCOL TEAM ET AL, "Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial", THE LANCET, THE LANCET PUBLISHING GROUP, GB, vol. 372, no. 9653, doi:10.1016/S0140-6736(08)61591-3, ISSN 0140-6736, (20081129), pages 1881 - 1893, (20081127), XP025710769 DOI: http://dx.doi.org/10.1016/S0140-6736(08)61591-3 | - CHINSANGARAM J ET AL, "Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20030101), vol. 77, no. 2, doi:10.1128/JVI.77.2.1621-1625.2003, ISSN 0022-538X, pages 1621 - 1625, XP008110911 DOI: http://dx.doi.org/10.1128/JVI.77.2.1621-1625.2003 | - Anonymous, "General Approach to the Poisoned Patient", Medical toxicology, (20040101), page 512, XP055309834 | - G Demers, "Interferon-[alpha]2b Secretion by Adenovirus-Mediated Gene Delivery in Rat, Rabbit, and Chimpanzee Results in Similar Pharmacokinetic Profiles", Toxicology and Applied Pharmacology, (20020401), vol. 180, no. 1, doi:10.1006/taap.2002.9372, ISSN 0041-008X, pages 36 - 42, XP055069557 DOI: http://dx.doi.org/10.1006/taap.2002.9372 | - Brian B. Gowen ET AL, "Use of Recombinant Adenovirus Vectored Consensus IFN-[alpha] to Avert Severe Arenavirus Infection", PL o S One, US, (20110101), vol. 6, no. 10, doi:10.1371/journal.pone.0026072, ISSN 1932-6203, pages e26072 - e26072, XP055309839 DOI: http://dx.doi.org/10.1371/journal.pone.0026072 | - GUTIERRO I ET AL, "Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres", VACCINE, ELSEVIER LTD, GB, (20020522), vol. 20, no. 17-18, doi:10.1016/S0264-410X(02)00146-9, ISSN 0264-410X, pages 2181 - 2190, XP004353923 DOI: http://dx.doi.org/10.1016/S0264-410X(02)00146-9 | - HUANG J ET AL, "A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats", VACCINE, ELSEVIER LTD, GB, (20041221), vol. 23, no. 6, doi:10.1016/J.VACCINE.2004.06.049, ISSN 0264-410X, pages 794 - 801, XP004637086 DOI: http://dx.doi.org/10.1016/j.vaccine.2004.06.049 | - A Isaacs ET AL, "Virus Interference. I. The Interferon", Proc R Soc Lond, (19570101), vol. 147, pages 258 - 267, XP055309879 DOI: http://dx.doi.org/10.1098/rspb.1957.0048 | - Douglas J Jolly ET AL, "Adenoviral Vectors: History and Perspective", Concepts in Medicine, Wiley-Liss, (20080101), pages 39 - 54, ISBN 978-0-471-70320-4, XP055309935 DOI: http://dx.doi.org/10.1002/9780470184585.ch4 | - J. G. Julander ET AL, "Treatment of Yellow Fever Virus with an Adenovirus-Vectored Interferon, DEF201, in a Hamster Model", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, US, (20110207), vol. 55, no. 5, doi:10.1128/AAC.01635-10, ISSN 0066-4804, pages 2067 - 2073, XP055309941 DOI: http://dx.doi.org/10.1128/AAC.01635-10 | - V. Keedy ET AL, "Phase I Study of Adenovirus p53 Administered by Bronchoalveolar Lavage in Patients With Bronchioloalveolar Cell Lung Carcinoma: ECOG 6597", JOURNAL OF CLINICAL ONCOLOGY, US, (20080828), vol. 26, no. 25, doi:10.1200/JCO.2007.15.6927, ISSN 0732-183X, pages 4166 - 4171, XP055309943 DOI: http://dx.doi.org/10.1200/JCO.2007.15.6927 | - Micheal R Knowles ET AL, "A CONTROLLED STUDY OF ADENOVIRAL-VECTOR-MEDIATED GENE TRANSFER IN THE NASAL EPITHELIUM OF PATIENTS WITH CYSTIC FIBROSIS", New England Journal of Medicine, (19950928), vol. 333, pages 823 - 831, XP055309950 | - KUMAKI Y ET AL, "Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 89, no. 1, ISSN 0166-3542, (20110101), pages 75 - 82, (20110101), XP027586729 | - MORAES M P ET AL, "Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine", VACCINE, ELSEVIER LTD, GB, (20031212), vol. 22, no. 2, doi:10.1016/S0264-410X(03)00560-7, ISSN 0264-410X, pages 268 - 279, XP004472593 DOI: http://dx.doi.org/10.1016/S0264-410X(03)00560-7 | - Mary Ann Liebert ET AL, "Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee", Human gene therapy, United States, doi:10.1089/10430340152712629, (20020101), pages 3 - 13, URL: http://osp.od.nih.gov/sites/default/files/adsat_rpt.pdf, XP055309953 DOI: http://dx.doi.org/10.1089/10430340152712629 | - Frances h. Priddy ET AL, "Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type 5 HIV-1 Clade B gag/pol/nef Vaccine in Healthy Adults", CLINICAL INFECTIOUS DISEASES, US, (20080601), vol. 46, no. 11, doi:10.1086/587993, ISSN 1058-4838, pages 1769 - 1781, XP055309956 DOI: http://dx.doi.org/10.1086/587993 | - T Reid ET AL, "Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial", Gene Therapy, GB, (20011101), vol. 8, no. 21, doi:10.1038/sj.gt.3301512, ISSN 0969-7128, pages 1618 - 1626, XP055309958 DOI: http://dx.doi.org/10.1038/sj.gt.3301512 | - Donald F. Smee ET AL, "Therapy and Long-Term Prophylaxis of Vaccinia Virus Respiratory Infections in Mice with an Adenovirus-Vectored Interferon Alpha (mDEF201)", PLoS ONE, (20111013), vol. 6, no. 10, doi:10.1371/journal.pone.0026330, page e26330, XP055309962 DOI: http://dx.doi.org/10.1371/journal.pone.0026330 | - SULLIVAN N J ET AL, "Development of a preventive vaccine for Ebola virus infection in primates", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, (20001130), vol. 408, no. 6812, doi:10.1038/35046108, ISSN 0028-0836, pages 605 - 609, XP002242909 DOI: http://dx.doi.org/10.1038/35046108 | - SUMIDA SHAWN M ET AL, "Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20050601), vol. 174, no. 11, ISSN 0022-1767, pages 7179 - 7185, XP002385299 | - THOMAS C E ET AL, "PROGRESS AND PROBLEMS WITH THE USE OF VIRAL VECTORS FOR GENE THERAPY", NATURE REVIEWS GENETICS, MACMILLAN MAGAZINES, GB, (20030501), vol. 4, no. 5, doi:10.1038/NRG1066, pages 346 - 358, XP008061799 DOI: http://dx.doi.org/10.1038/nrg1066 | - Jonathan B. Zuckerman ET AL, "A Phase I Study of Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to a Lung Segment of Individuals with Cystic Fibrosis", Human Gene Therapy, US, (19991210), vol. 10, no. 18, doi:10.1089/10430349950016384, ISSN 1043-0342, pages 2973 - 2985, XP055309970 DOI: http://dx.doi.org/10.1089/10430349950016384 | - Jeffrey D Turner, "Declaration of Jeffrey D. Turner PH.D. UNDER 37 C.F.R. & 1.132", (20120709), pages 1 - 8, XP055309973 | - ALBERTI A, "INTERFERON ALFACON-1: A NOVEL INTERFERON FOR THE TREATMENT OF CHRONIC HEPATITIS C", BIODRUGS,, (19990101), vol. 12, no. 5, doi:10.2165/00063030-199912050-00003, ISSN 1173-8804, pages 343 - 357, XP008072415 DOI: http://dx.doi.org/10.2165/00063030-199912050-00003 | by applicant | US4450103 | US4588585 | US4695623 | US4737462 | US4897471 | US4959314 | WO9420069 | US5372808 | US5437267 | US5522385 | US5522378 | WO9632149 | US5654007 | WO9742323 | WO9741833 | US5738845 | WO9817801 | US5775320 | WO9829096 | US5785049 | US5789245 | US5826570 | US5846526 | US5855564 | US5915378 | US5922354 | US5934272 | US5957124 | US5960792 | US5976574 | US5985248 | US5993783 | US5994314 | US5997848 | US6001336 | US6004583 | US6060450 | US6068199 | US6093550 | US6204022 | US6303582 | US6361769 | US6398774 | US6413539 | US6565853 | US6605302 | US6715485 | US2004112378 | US2004112379 | US2004149289 | US2004247565 | US2005028812 | US2005072430 | US6894033 | US6936257 | US2005235992 | US6962978 | US2006096589 | US2006169278 | US7097827 | US7105154 | US7166575 | US2007039614 | WO2007044083 | US7235391 | US7238344 | US2007186927 | US2007243163 | US2007274950 | US7347201 | US7371373 | US7387788 | US2008161771 | US2008163874 | US2008223363 | US7442527 | US7442380 | US7482024 | US7481212 | US7481218 | US7538122 | US7669597 |